Introduction {#S1}
============

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by the inflammation of synovial tissue, which leads to progressive cartilage and bone destruction. The development of RA is attributed to an uncontrolled activation of auto-reactive CD4+ T cells ([@B1], [@B2]). Dendritic cells (DCs) play a pivotal role in the pathogenesis of RA through presentation of autoantigen peptides on major histocompatibility complex (MHC) molecules ([@B3], [@B4]). The secretion of pro-inflammatory cytokines by DCs further promotes the maturation of bystander DCs and drives the differentiation of T helper type 1 (Th1) and Th17 cells, both involved in the pathology and progression of RA ([@B1], [@B2]).

Current treatment of RA includes the use of immunosuppressive drugs and/or biologic therapies ([@B2], [@B5]). All of them require lifelong treatment and, thus, new therapeutic strategies are needed to suppress inflammation and re-establish self-tolerance without affecting the whole patient's immune system. In particular, research has focused on the generation of tolerogenic DCs (TolDCs) capable of modulating antigen-specific immune responses ([@B6], [@B7]). TolDCs may induce antigen-specific tolerance through induction of anergy, deletion of auto-reactive T cells ([@B8], [@B9]), generation and expansion of regulatory T cells (Treg) ([@B10], [@B11]), and/or the establishment of an anti-inflammatory environment through secretion of IL-10 and/or transforming growth factor beta (TGF-β) ([@B12]).

Different strategies have been described for the *in vitro* generation of TolDCs derived from peripheral blood monocytes, including modulation by IL-10 or TGF-β ([@B8], [@B13]), dexamethasone ([@B14]), Bay11-7082 ([@B15]), rapamycin ([@B16]), aspirin ([@B17]) or vitamin D3 ([@B18]), short stimulation with lipopolysaccharide (LPS) ([@B19]), or its non-toxic analog monophosphoryl lipid A (MPLA) ([@B20]). Although TolDC properties may vary according to the applied protocol, TolDC features include reduced expression of co-stimulatory and antigen presentation molecules, low IL-12 production, and suppression of effector T cell responses *in vitro* ([@B21], [@B22]). Application of TolDCs for RA treatment has been successfully tested in animal models ([@B23], [@B24]). Phase I clinical trials using *in vitro* modified autologous TolDCs demonstrated feasibility and safety in patients with type 1 diabetes ([@B25]) and RA ([@B15], [@B26]).

Recently, we described a shortened protocol for the differentiation of monocytes from healthy donors into TolDCs, using dexamethasone for immunomodulation, and current good manufacture practice (cGMP)-grade MPLA to trigger toll-like receptor (TLR)-mediated activation, including the upregulation of chemokine receptors that mediate the migration to secondary lymphoid organs ([@B20]). These MPLA-tDCs expressed low levels of co-stimulatory molecules and maturation markers, and secreted high levels of IL-10 and low levels of IL-12. In functional analyses, they migrated to lymphoid chemokines and induced lower levels of T cell proliferation and cytokine production than mature DCs ([@B27]).

Monocytes from RA patients were demonstrated to exhibit a highly inflammatory profile ([@B28], [@B29]) and studies investigating their capacity to develop into functional TolDCs *in vitro* showed contradictory results ([@B30], [@B31]), suggesting that disease-associated factors might affect TolDC differentiation. To date, there are no studies comparing the transcriptomes of immature, mature, and modulated monocyte-derived DCs (moDCs) from RA patients and healthy subjects.

Therefore, the aim of the present study was to translate our MPLA-tDC protocol to moDCs derived from RA patients, and to characterize them at phenotypic, functional, and transcriptional level in order to validate their applicability as autologous cellular therapy to restore antigen-specific tolerance in RA.

Materials and Methods {#S2}
=====================

The minimum information about tolerogenic antigen-presenting cells (MITAP) checklist ([@B32]) was followed for the preparation of this manuscript.

Blood Samples and Synovial Fluid {#S2-1}
--------------------------------

Twenty-seven leukapheresates from patients with active RA and 28 buffy coats from healthy donors were obtained from Hospital del Salvador and Hospital Clínico de la Universidad de Chile. Demographic characteristics of patients and healthy donors are detailed in Table S1 in Supplementary Material. All RA patients fulfilled ACR criteria for RA diagnosis and received treatment as described in Table S1 in Supplementary Material. Subjects signed an informed written consent according to the Declaration of Helsinki and all procedures were approved by the Ethics Committees of the Facultad de Medicina and Hospital Clínico from Universidad de Chile, and Hospital del Salvador.

Synovial fluid (SF) was collected through arthrocentesis of inflamed knees of one RA patient. Removal of cells from SF was done by centrifugation at 1800 rpm for 5 min. The acellular fraction was treated with hyaluronidase (100 U/ml) for 60 min at 37°C to reduce viscosity and centrifuged at 1800 rpm for 10 min before passing through a 0.2-μm filter. Protein concentration was quantified using the BCA method (Sigma-Aldrich, MO, USA) at A~562~ (Table S1 in Supplementary Material).

Generation of Monocyte-Derived DCs {#S2-2}
----------------------------------

Monocytes were isolated by negative selection using RosetteSep Human Monocyte enrichment cocktail (Stemcell Technologies, Vancouver, BC, Canada) according to manufacturer's instructions. moDCs were generated as previously described ([@B20]) in AIM-V medium (Gibco BLR, Grand Island, NE, USA), supplemented with 500 U/ml of recombinant human GM-CSF and IL-4 (eBioscience, San Diego, CA, USA) within 5 days. At days 3 and 4, cells were modulated with 1 μM dexamethasone (tDCs) (Sigma-Aldrich, St. Louis, MO, USA) and activated with 1 μg/ml cGMP-grade MPLA (MPLA-tDCs) (Avanti, Alabaster, AL, USA). Untreated/immature DCs (iDCs) and MPLA-matured DCs (mDCs) were used as controls.

Flow Cytometry {#S2-3}
--------------

Antibodies used for analysis were anti-human CD11c APC, CD80 FITC, CD83 FITC, HLA-DR FITC, CD40 PE, CD86 PE, TLR-2 PE, CXCR4 PE, CCR7 PE, CD4 PECy7, and IFN-γ APC (all from eBioscience). Cells were resuspended in PBS supplemented with fetal bovine serum (FBS) (HyClone Thermo Scientific, Logan, UT, USA), stained with specific antibodies, fixed with IC fixation buffer (eBioscience) and resuspended in FACSFlow buffer (Becton Dickinson, San Diego, CA, USA) for subsequent analysis. Data were acquired on a FACSAria III with FACSDiva v6.1.3 software (both Becton Dickinson) and analyzed by FlowJo software (Treestar, USA).

Cytokine Production {#S2-4}
-------------------

1 × 10^5^ DCs were incubated for 24 h with or without CD40L-transfected irradiated NIH3T3 cells at 1:1 ratio in AIM-V medium in 96-well U bottom plates (BRAND, Wertheim, Germany). Supernatants of co-cultures with NIH3T3 cells or T cells were recovered and stored at −80°C until quantification of IL-10, IL-12p70, IL-23, TNF-α, TGF-β1(active), and IL-17A by ELISA (eBioscience).

Chemotaxis Assay {#S2-5}
----------------

Migration was assessed *in vitro* using a transwell system (24-well, pore size 5 μm polycarbonate inserts; Corning Costar, USA). 1.5 × 10^5^ DCs from RA patients were seeded in the upper chamber and AIM-V medium alone or supplemented with 250 ng/ml of SDF-1α/CXCL12 or MIP-3β/CCL19 (PeproTech, Rocky Hill, CT, USA) was added to the lower chamber. After 4-h incubation at 37°C and 5% CO~2~, DCs in the lower chamber were counted by flow cytometry. DCs migration is expressed as "migration index" (migration toward chemokines/migration toward medium).

Assessment of CD4+ T Cell-Stimulatory Capacity of DCs {#S2-6}
-----------------------------------------------------

CD4+ T cells were isolated by negative selection using RosetteSep Human T cell enrichment cocktail (Stemcell Technologies, Vancouver, BC, Canada) and labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE).

For allogeneic assays, DCs from RA patients were co-cultured with CD4+ T cells from healthy donors. For assessment of antigen-specific CD4+ T cell activation, DCs from RA patients, loaded with 1 μg/ml tuberculin purified protein derivative (PPD; Staten Serum Institute, Copenhagen, Denmark) or 200 μg/ml SF proteins 4 h prior to activation with MPLA, were co-cultured with autologous CD4+ T cells at a DC:T cell ratio of 1:2 in RPMI medium (HyClone Thermo Scientific) with 10% FBS in 96-well U bottom plates for 6 days ([@B20]). CD4+ T cells alone, or stimulated with anti-human CD3 (eBioscience) were used as negative and positive controls, respectively. Supernatants were collected to assess cytokine secretion. For intracellular IFN-γ detection, 50 ng/ml phorbol-12-myriastate-13-acetate (PMA, Sigma-Aldrich), 1 μg/ml ionomycin (Sigma-Aldrich), and 1 μg/ml brefeldin-A (eBioscience) were added for the last 5 h of culture. Proliferation and IFN-γ production of CD4+ T cells were analyzed by flow cytometry.

RNA Isolation and Microarray Analysis {#S2-7}
-------------------------------------

Total RNA was isolated from 5 × 10^5^ moDCs using RNeasy Mini Kit (Qiagen, Hilden, Germany) according to manufacturer's instructions. Yield and quality of RNA samples were evaluated with NanoDrop 1000 spectrophotometer (Thermo Scientific, Waltham, MA, USA) and RNA Integrity (RIN score) was analyzed with Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) or LabChip GX/GX II (Caliper LifeSciences, Hopkinton, MA USA). A total of 76 samples, corresponding to DCs derived from 9 RA patients and 10 healthy donors under 4 experimental conditions were considered for microarray analysis (Figure S1 in Supplementary Material). All RNA samples used for microarrays showed A260/A280 values between 1.8 and 2.2, and RIN scores \>7. RNA samples were reverse transcribed, amplified, and labeled using a Illumina^®^ TotalPrepTM RNA Amplification Kit, and cRNA was hybridized onto Illumina Human HT-12 v4 BeadChips (Illumina, San Diego, CA, USA), covering the whole human genome. Expression data were extracted with GenomeStudio Project Software from Illumina.

Data Exploration and Statistical Methods {#S2-8}
----------------------------------------

Friedman repeated measures test (differences between culture conditions) or Kruskal--Wallis test (differences between RA patients and healthy donors) and Dunn's post test were used for comparisons. Wilcoxon signed-rank test was used to compare migration of different DC populations. Analyses were performed using Prism 5.01 software (Graphpad, San Diego, CA, USA). *P*-values ≤0.05 were considered significant.

Microarray data were log-transformed and normalized using the preprocess Core package v1.28.0 from Bioconductor. Principal component analysis (PCA) was performed using the PCA function of mixOmics package v5.0-3 ([@B33]) of R software ([@B34]), in order to assess differences in differentiation protocols and to detect outliers that might affect downstream analyses. Differentially expressed (DE) genes in modulated DCs compared to unstimulated DCs (iDCs) were identified with the Maanova package v1.36.0 *T*-test for gene pairwise comparisons ([@B35]). A false discovery rate (FDR) of 0.05 or lower was used as cut-off value. K-means clustering of DE genes between MPLA-tDCS and iDCs was performed using the cluster package. Detailed analyses are described in Figure S1 in Supplementary Material.

Results {#S3}
=======

MPLA-tDCs from RA Patients Exhibit a Tolerogenic Phenotype {#S3-1}
----------------------------------------------------------

The phenotype of different DCs subsets, generated from monocytes of RA patients and healthy subjects was analyzed by flow cytometry. All DC populations contained \>95% CD11c+ cells and exhibited high CD1a and low CD14 expression, while their viability ranged from 70 to 90% and did not differ between RA patients and healthy donors (data not shown). In comparison to mDCs, dexamethasone-treated and MPLA-activated DCs (MPLA-tDCs) showed reduced expression of CD86 and CD83, similar to iDCs (Figure [1](#F1){ref-type="fig"}A). Expression of CD40 and CD80 was also reduced in MPLA-tDCs compared to mDCs (Figure [1](#F1){ref-type="fig"}A and data not shown). In accordance with the previously described elevated expression of TLR2 on TolDC generated with dexamethasone, vitamin D3, and MPLA ([@B31]), we observed that TLR2 expression was significantly increased on MPLA-tDCs as compared to iDCs and mDCs (Figure [1](#F1){ref-type="fig"}A). No significant differences were found concerning the phenotype of DC subsets between healthy subjects and RA patients (Figure [1](#F1){ref-type="fig"}A). Furthermore, exposure of RA-derived MPLA-tDCs to inflammatory stimuli, such as SF or TNF, did not affect the tolerogenic phenotype of these cells (Figure [1](#F1){ref-type="fig"}B).

![**MPLA-tDCs from rheumatoid arthritis patients and healthy controls display a tolerogenic phenotype that remains unaffected under pro-inflammatory conditions**. **(A)** Monocytes from patients with rheumatoid arthritis (RA) (*black closed symbols*) and from healthy control (HC) subjects (*gray open symbols*) were differentiated into DCs in the presence of GM-CSF and IL-4 within 5 days. For tolerization, DCs were conditioned with dexamethasone (Dex) during 48 h and were additionally activated with MPLA for the last 24 h of culture (MPLA-tDCs). Surface expression levels of CD86, CD40, CD83, HLA-DR, and TLR2 were assessed by flow cytometry. Dot plots show all data points and median values are indicated as a line. **(B)** MPLA-tDCs from RA patients were incubated for 72 h in the presence of synovial fluid (200 μg/ml) or TNFα (10 ng/ml), and the expression of phenotypic markers was analyzed. Untreated iDCs were used as controls. Statistical differences were calculated using either Kruskal--Wallis test (comparison between HC and RA) or Friedman test (comparison between culture conditions) and Dunn's multiple comparison was used as post test (\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001).](fimmu-07-00458-g001){#F1}

MPLA-tDCs from RA Patients Show an Anti-Inflammatory Cytokine Profile {#S3-2}
---------------------------------------------------------------------

Consistent with our previous findings in healthy subjects ([@B20]), we found that MPLA-tDCs from RA patients produced 10-fold more IL-10 and 5-fold less IL-12p70 than mDCs in response to CD40 ligation (Figure [2](#F2){ref-type="fig"}). Although IL-10 levels tended to be higher in DCs from RA patients than in those from healthy subjects, these differences were not significant. MPLA-tDCs secreted significantly lower levels of TNF-α and IL-23 and higher levels of TGF-β1 than mDCs. The cytokine profiles of MPLA-tDCs and iDCs derived from RA patients were similar to those from healthy donors (Figure [2](#F2){ref-type="fig"}). Interestingly, the rate of IL-10/IL-12 in MPLA-tDCs from RA patients was significantly higher than that observed in mDCs (Figure [2](#F2){ref-type="fig"}B). Mirroring their behavior toward SF and TNFα exposure, MPLA-tDCs maintained their low expression of CD86, CD80, CD40, and CD83, and the high expression of TLR2 upon CD40 engagement (data not shown).

![**MPLA-tDCs from rheumatoid arthritis patients exhibit an anti-inflammatory cytokine profile**. Monocyte-derived DC (moDC) subsets from rheumatoid arthritis (RA) patients (*black closed symbols*) and healthy control subjects (HC; *gray open symbols*) were cultured with CD40L-transfected NIH3T3 cells at 1:1 ratio for 24 h. **(A)** Concentrations of IL-10, IL-12, IL-23, TNF-α, and active TGF-β1 were determined in culture supernatants of moDCs by ELISA. **(B)** Bar chart with values of IL-10/IL-12 ratio of different moDC subsets from RA patients. Dot plots show all data points and horizontal lines indicate median values. Statistical differences were calculated using Kruskal--Wallis test (comparison of HC and RA) or Friedman test (comparison of DC types) and Dunn's multiple comparison post test (\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001).](fimmu-07-00458-g002){#F2}

MPLA-tDCs from RA Patients Migrate toward Secondary Lymphoid Tissue Chemokines {#S3-3}
------------------------------------------------------------------------------

We investigated the expression of lymph node homing chemokine receptors on DCs from RA patients and their migratory response toward the corresponding chemokines in a transwell system. Expression of CXCR4 and CCR7 was 2.5 fold higher on MPLA-tDCs than in iDCs and significantly enhanced when compared to tDCs (Figure [3](#F3){ref-type="fig"}A). MPLA-tDCs and mDCs also showed high migration indexes toward the CXCR4 and CCR7 ligands, CXCL12 and CCL19, respectively, exhibiting a higher migratory ability towards lymphoid chemokines than tDCs (Figure [3](#F3){ref-type="fig"}B).

![**MPLA-tDCs from rheumatoid arthritis patients display the capacity to migrate toward CCR7 and CXCR4 ligands**. After 5 days of culture, the migratory capacity of MPLA-tDC (*dark gray*), tDCs (*white*) and mDCs (*light gray*) from rheumatoid arthritis (RA) patients was studied *in vitro*. **(A)** The percentage of CD11c+ DCs expressing CXCR4 or CCR7 was determined by flow cytometry (*n* = 15). Fold expression changes on receptor expression on mDCs, tDCs and MPLA-tDCs compared to untreated iDCs are shown. **(B)** Transwell assays were used to assess migration of DCs in response to 250 ng/ml of CXCL12 or CCL19 (*n* = 12). Migration index indicates the quotient of cells that migrated toward a specific chemokine divided by cells that migrated toward medium alone. Box plots show median, 25- and 75%-quartile, minimum and maximum values, respectively. Wilcoxon signed-rank test was used to evaluate statistical differences between MPLA-tDCs, tDCs, and mDCs (\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001).](fimmu-07-00458-g003){#F3}

MPLA-tDCs from RA Patients Modulate Allogeneic and Autologous T Cell Responses {#S3-4}
------------------------------------------------------------------------------

In order to evaluate T cell responses, MPLA-tDCs, mDCs, or iDCs of RA patients were cultured with allogeneic CD4+ T cells from healthy donors in mixed leukocyte reactions. When compared to mDCs, CD4+ T cell proliferative responses (median %CFSE^low^CD4+ T cells in co-cultures with: iDCs = 13.9; mDCs = 65.4; MPLA-tDCs = 22.8; mDCs vs. MPLA-tDCs: *P* = 0.001) and IFN-γ production (median %IFN-γ + CFSE^low^CD4+ T cells in co-cultures with: iDCs = 3.4; mDCs = 29.7; MPLA-tDCs = 3.0; mDCs vs. MPLA-tDCs: *P* = 0.005) to MPLA-tDCs were significantly reduced (Figure [4](#F4){ref-type="fig"}).

![**MPLA-tDCs modulate CD4+ T cell responses to synovial antigens**. Monocytes (*n* = 6--9) were differentiated into mDCs and MPLA-tDCs as described in the Section "[Materials and Methods](#S2){ref-type="sec"}." At day 4 of DC generation, 4 h prior to stimulation with MPLA, mDCs and MPLA-tDCs were loaded with 1 μg/ml tuberculin purified protein derivative (PPD), 200 μg/ml synovial fluid (SF), or left unloaded for further 24 h. For the assessment of their T cell-stimulatory capacity, antigen-loaded or unloaded mDCs and MPLA-tDCs were co-cultured with autologous CFSE-labeled CD4+ T cells in a ratio of 1:2 (DC:T cell) for 6 days. To detect IFN-γ intracellularly, cells were stimulated with 50 ng/ml phorbol-12-myriastate-13-acetate and 1 μg/ml ionomycin in the presence of 1 μg/ml brefeldin-A. Proliferation-associated CFSE dilution and IFN-γ production of CD4+ T cells were analyzed by flow cytometry. **(A)** Representative dot plots and **(B)** graphic representation of the percentage of IFN-γ-producing proliferating (CFSE^low^) CD4+ T cells are shown. **(C)** IL-17A secretion was measured in supernatants of co-cultures by ELISA. **(B,C)**, Box plots show median, 25- and 75%-quartiles and both extreme values (\**P* \< 0.05).](fimmu-07-00458-g004){#F4}

To investigate the capacity of MPLA-tDCs to present antigens and thereby activate antigen-specific memory T cells, DCs from RA patients were loaded with PPD or SF and co-cultured with autologous CD4+ T cells. While mDCs induced potent proliferation and IFN-γ production of CD4+ T cells, MPLA-tDCs stimulated poor proliferation and IFN-γ expression in SF-specific CD4+ T cells (Figures [4](#F4){ref-type="fig"}A,B). Only mDCs but not MPLA-tDCs induced the secretion of IL-17A by SF-specific CD4+ T cells (Figure [4](#F4){ref-type="fig"}C). Proliferation, IFN-γ production, and IL-17A secretion of CD4+ T cells in co-culture with PPD-loaded MPLA-tDCs were slightly, but not significantly lower than those in co-culture with PPD-loaded mDCs (Figures [4](#F4){ref-type="fig"}B,C). Taken together, these results show that MPLA-tDCs obtained from RA patients have an impaired capacity to induce inflammatory CD4+ T cell responses.

Modulation with Dexamethasone and MPLA Generates a Particular Transcriptional Profile in DCs, Which Overcomes RA-Associated Effects {#S3-5}
-----------------------------------------------------------------------------------------------------------------------------------

To confirm that modulation with dexamethasone and MPLA confers tolerogenic features to DCs, regardless of whether they are derived from healthy subjects or RA patients, we analyzed transcriptomes of four different DC preparations, generated from monocytes of healthy donors and RA patients. RNA samples from different DCs preparations were subjected to whole-genome microarray analysis and DE genes between samples were defined by FDR of 0.05 or lower (Figure S1 in Supplementary Material). First, we investigated the effect of different stimuli for DC generation/modulation ("protocol"), health state of the donor ("disease"), or the combination of both ("interaction"), on gene expression (Figure [5](#F5){ref-type="fig"}). The differentiation protocol (unstimulated: iDCs, dexamethasone: tDCs, MPLA: mDCs, and dexamethasone plus MPLA: MPLA-tDCs) had the main impact on gene expression, affecting 43% of the DC transcriptome (Figure [5](#F5){ref-type="fig"}A). The "disease" factor alone did not affect global gene expression, while the expression of 11 transcripts was altered by a disease--protocol interaction (Figure [5](#F5){ref-type="fig"}A; Table S2 in Supplementary Material). This was in agreement with a Principal Component Analysis (PCA), in which the first two dimensions (Component 1, 27.1% variance; Component 2, 16.4% variance) noticeably separated the samples according to the protocol, while no separation between RA and healthy donors was detected (Figure [5](#F5){ref-type="fig"}B).

![**Conditioning with dexamethasone and MPLA induces similar transcriptional profiles on monocyte-derived DCs from rheumatoid arthritis patients and healthy controls and counterpoints disease-associated effects on gene expression**. **(A)** Venn diagram displaying numbers of differentially expressed (DE) transcripts due to differentiation protocol (iDCs, mDCs, tDCs, or MPLA-tDCs), presence of disease (healthy controls: HC, or rheumartoid arthritis: RA) or interaction of protocol and disease. **(B)** Principal component analysis using the first two components separates samples according to their variance. **(C,D)** Pairwise comparison between moDCs from RA patients and HC were performed for each differentiation protocol separately using *t*-test. **(C)** 44 DE genes found exclusively in iDCs were hierarchically clustered. Genes with known or potential association to RA are highlighted in red color. **(D)** Changes in means of expression of selected RA-associated DE genes in iDCs vs. MPLA-tDCs were shown for HC and RA patients. iDCs, unstimulated immature DCs; tDCs, dexamethasone-modulated TolDCs; mDCs, MPLA-matured DCs; MPLA-tDCs, dexamethasone-modulated MPLA-activated TolDCs.](fimmu-07-00458-g005){#F5}

To unravel potential effects of RA on gene expression, which might have been missed by the previously applied three-factor model, we performed pairwise comparisons between RA- and healthy donor-derived DCs separately for each protocol. Only when comparing untreated DCs (iDCs) of RA patients and healthy controls (HCs), the analysis revealed 44 DE transcripts (Figure [5](#F5){ref-type="fig"}C). Differences in the expression of these genes were also present in mDCs, albeit not significant, and completely disappeared in tDCs and MPLA-tDCs (Figure [5](#F5){ref-type="fig"}C). Among these 44 DE genes, we identified 12 genes with known association to RA (Figure [5](#F5){ref-type="fig"}C; Table S2 in Supplementary Material) due to their involvement in inflammatory processes, such as NF-kB activation (BCL10, MAP3K7/TAK1, MAPK1/ERK), inflammation (ALOX15, MAPK1/ERK, ATG3, ATXN3, VCL), induction of differentiation and/or activation of Th17 cells (BCL10, CD200R1), as well as chemotaxis and cellular infiltration of synovia (CCR2, CD200R1, SPN/CD43) ([@B36]--[@B40]). In contrast to HCs, the expression of these RA-associated genes changed markedly in DCs upon modulation with dexamethasone alone or in combination with MPLA (Figures [5](#F5){ref-type="fig"}C,D). Expression of RA-associated genes, which were upregulated in iDCs of RA patients, declined to levels of HCs in RA-derived MPLA-tDCs. Therefore, modulation with dexamethasone and MPLA removed differences at transcriptional level between moDCs from RA patients and healthy individuals.

Discussion {#S4}
==========

As prerequisite for clinical trials using TolDCs for RA therapy, differentiation protocols have to be tested with cells from patients. Here we demonstrate that treatment with dexamethasone and MPLA overcomes disease-associated effects on gene transcription in moDCs and promotes a tolerogenic phenotype with reduced capacity to induce inflammatory responses in antigen-specific T cells.

Dexamethasone, a corticosteroid widely used to treat autoimmune disorders, has been shown to modulate maturation and function of DCs *in vitro* and *in vivo*, validating its use for TolDC generation ([@B41], [@B42]). Additionally, activation through TLR4 is required to endow TolDCs with the ability to process and present exogenous antigen on MHC class II molecules and to acquire the capacity to migrate to secondary lymphoid tissues, the sites of interaction with naïve T cells ([@B43]). Functionally, glucocorticoids, such as dexamethasone, suppress pro-inflammatory programs induced by TLR activation, while potentiating TLR-induced anti-inflammatory responses ([@B44], [@B45]). To meet cGMP requirements, we used the non-toxic TLR4 ligand, MPLA, instead of LPS, for DC activation. MPLA exhibits a potent immunostimulatory capacity ([@B46]), albeit less than LPS, and has been proven to be an effective and safe adjuvant in animal studies and clinical trials testing next-generation vaccines ([@B43], [@B47]). We previously demonstrated that dexamethasone-modulated and MPLA-activated DCs display a similar tolerogenic phenotype as DCs treated with dexamethasone alone, indicating that MPLA does not affect immunoregulatory properties of dexamethasone-conditioned DCs ([@B20]). Stoop and co-workers also demonstrated in an experimental arthritis model that DCs modulated with dexamethasone and vitamin D3, and activated with LPS retained their tolerogenic functions, even in a pro-inflammatory environment *in vivo* ([@B48]). According to previous reports describing the properties of TolDCs derived from healthy donors ([@B31], [@B43]), MPLA-tDCs from RA patients showed reduced expression of co-stimulatory molecule CD86, the coactivator CD40, and the maturation marker CD83, as well as high expression of MHC class II, similar to mDCs. Since these cells will encounter a highly pro-inflammatory environment when transferred into RA patients, it is crucial that they are able to retain their regulatory features under these conditions. Exposure of MPLA-tDCs to inflammatory stimuli, such as TNF and SF, which are also present in RA, did not affect their tolerogenic phenotype. Accordingly, their capacity to induce hyporresponsiveness of autologous CD4+ T cells was not impaired upon challenge with SF. The anti-inflammatory cytokine profile of MPLA-tDCs from RA patients points to their immunomodulatory abilities. Correspondingly, RA patient-derived MPLA-tDCs did not promote Th1 and Th17 responses, probably due to reduced IL-12p70 and IL-23 production, and the suppressive effect of other MPLA-tDC-derived molecules, such as IL-10 and TGF-β. This induction of T cell hyporesponsiveness is in accordance with our recent findings, unraveling that MPLA-tDCs from HCs do not promote classical Treg, but rather induce hyporesponsive anergic T cells capable of suppressing Th1 and Th17 responses ([@B49]).

Lymph node trafficking is a critical feature of TolDCs when intended to use for cellular therapy in autoimmunity ([@B50]). We showed that a significant proportion of MPLA-tDCs from RA patients expressed lymph node homing receptors CCR7 and CXCR4 and migrated *in vitro* in response to CCL19 and CXCL12, albeit less than mDCs. It is conceivable that inoculated MPLA-tDCs might exert their tolerogenic functions not only in lymph nodes but also locally within the inflamed joint, since it has been shown that dexamethasone-treated LPS-activated TolDCs express also CXCR3 and migrate toward its ligand CXCL10/IP10 associated with inflamed tissues ([@B51]).

The capacity of TolDCs to present antigen in a MHC class II context is critical for the induction of auto-antigen-specific tolerance ([@B18]). The fact that MPLA-tDCs from RA patients express HLA-DR in amounts comparable to mDCs indicates that dexamethasone does not affect antigen presentation and that the poor T cell stimulatory capacity exhibited by MPLA-tDCs in allogeneic and autologous settings might rather be due to their anti-inflammatory properties than to an impairment of antigen presentation. We have recently demonstrated that MPLA-tDCs derived from HLA-DRB1\*0101+ RA patients are capable of efficiently presenting collagen peptide hCII(259--273) to the HLA-DR-restricted T cell hybridoma HCII-9.1 ([@B49]). Here, we demonstrate that MPLA-tDCs from RA patients are furthermore able to maintain their phenotypic features under inflammatory conditions and to induce hyporesponsiveness of autologous CD4+ T cells with specificity to synovial antigens. This is crucial considering that Th17 and Th1 responses lead to the progression of RA ([@B52]).

Monocytes from RA patients are highly activated and inflammatory ([@B28], [@B29]), suggesting that an early transcriptional program in monocytes might favor the development of highly inflammatory DCs *in vivo* and *in vitro*. This might also interfere with the acquirement of regulatory functions when generating TolDCs. Estrada-Capetillo and colleagues reported that moDCs from RA patients release high amounts of IL-6 and IL-23, and exhibit an increased capability to induce Th17 cells, while RA-derived TolDCs failed to induce Treg ([@B30]). However, Dr. Hilkens' group ([@B31]) and we have demonstrated that TolDCs generated from monocytes of RA patients possess tolerogenic features comparable to those of healthy individuals. The contradictory results concerning TolDC functionality lead us to further investigate these cells to a transcriptional level in order to identify or discard differences in gene expression between RA and HCs that could interfere with TolDC differentiation and function. Whole-genome expression analysis allowed us to confirm at a transcriptional level that treatment of moDCs with dexamethasone plus MPLA is sufficient to overcome RA-associated effects on gene expression in these cells. Despite individual data scattering, the transcriptional program of MPLA-tDCs remains consistent and allows clear separation from other DCs populations, particularly from untreated (iDCs) and mDCs, which still present disease-related effects on gene expression. This is in accordance with the absence of phenotypic and functional differences between MPLA-tDCs of RA patients and healthy subjects and suggests that MPLA-tDCs are suitable for autologous cellular therapy of RA.

Conclusion {#S5}
==========

Combined treatment with dexamethasone and MPLA overcomes RA-associated alterations in gene expression and induces TolDCs with a stable semi-mature phenotype, which migrate toward lymphoid chemokines, secrete regulatory cytokines, and induce hyporesponsiveness of synovial antigens-specific T cells. Thus, MPLA-tDCs are eligible for the development of an autologous tolerance-inducing cellular therapy for the treatment of RA.
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